ArticleMicrobial genomics2017
Genome-guided identification of novel head-to-tail cyclized antimicrobial peptides, exemplified by the discovery of pumilarin.
Article in Microbial genomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- Genomic and Functional Characterization of Bacillus amyloliquefaciens H6: A Potent Fengycin-Producing Biocontrol Agent Against Fusarium graminearum.Probiotics and antimicrobial proteins · 2026Article
- Article
- Bioprotective Strategies to ControlInternational journal of molecular sciences · 2025Review
- Leuconostoc lactis strain APC 3969 produces a new variant of cyclic bacteriocin leucocyclicin Q and displays potent anti-Clostridium perfringens activity.Scientific reports · 2025Article
- Article
- Effects of live Bacillus pumilus SG154 or a Lacticaseibacillus paracasei 327 postbiotic on apparent total tract nutrient digestibility and the immune function and fecal characteristics, metabolites, and microbiota of healthy adult dogs.Journal of animal science · 2025Article
- Raffinocyclicin is a novel plasmid-encoded circular bacteriocin produced byApplied and environmental microbiology · 2024Article
- Bacteriocin diversity, function, discovery and application as antimicrobials.Nature reviews. Microbiology · 2024Review
- Multi-omic analysis tools for microbial metabolites prediction.Briefings in bioinformatics · 2024Review
- In Silico Screening of Bacteriocin Gene Clusters within a Set of MarineInternational journal of molecular sciences · 2024Article
- Production of Pumilarin and a Novel Circular Bacteriocin, Altitudin A, byInternational journal of molecular sciences · 2024Article
- Leader- and Terminal Residue Requirements for Circularin A Biosynthesis Probed by Systematic Mutational Analyses.ACS synthetic biology · 2023Article
- Classification and Multifaceted Potential of Secondary Metabolites Produced byMolecules (Basel, Switzerland) · 2023Review
- Advances in the preclinical characterization of the antimicrobial peptide AS-48.Frontiers in microbiology · 2023Review
- Transient comparison of techniques to counter multi-drug resistant bacteria: prime modules in curation of bacterial infections.Frontiers in antibiotics · 2023Review
- Bioinformatic mining for RiPP biosynthetic gene clusters in Bacteroidales reveals possible new subfamily architectures and novel natural products.Frontiers in microbiology · 2023Article
- Mechanism of Action of Ribosomally Synthesized and Post-Translationally Modified Peptides.Chemical reviews · 2022Review
- Functional production of clostridial circularin A inFrontiers in microbiology · 2022Article
- Genome-guided purification and characterization of polymyxin A1 fromFrontiers in microbiology · 2022Article
- Transporter Protein-Guided Genome Mining for Head-to-Tail Cyclized Bacteriocins.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The need for novel antibiotics in an era where antimicrobial resistance is on the rise, and the number of new approved antimicrobial drugs reaching the market is declining, is evident. The underused potential of post-translationally modified peptides for clinical use makes this class of peptides interesting candidates. In this study, we made use of the vast amounts of available genomic data and screened all publicly available prokaryotic genomes (~3000) to identify 394 novel head-to-tail cyclized antimicrobial peptides. To verify these
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.